EZH2 and Miyoshi myopathy: On the basis of the growing body of data on PRC2 involvement in the MM pathophysiology, particularly its catalytic subunit EZH2, our group developed a theragnostic score called EZ-score, on the basis of the expression level of 15 genes that are sensitive to treatment with the EZH2 inhibitor EPZ-6438, associated with H3K27me3 and with a prognostic value in cohorts of patients with MM [93].